November 26, 2019
ViaCyte Inc., a privately held regenerative medicine company, is seeking residents of Alberta to participate in a promising JDRF-funded clinical trial in Edmonton. The purpose of this research is to determine the safety, tolerability and efficacy of PEC-Direct™ (also known as VC-02), an investigational therapy that may provide blood glucose control in a similar manner to what a “replacement pancreas” would do by producing insulin after it is surgically placed.
Eligible recruits include men and women who cannot have children between 18 and 65 years old who have lived with type 1 diabetes (T1D) for a minimum of five years. They must also have hypoglycemia unawareness and/or glucose variability yet be free of other diabetes complications. The study will last approximately two years, with participants visiting the clinic for about 18 visits during that period.
The goal is to develop a therapy that can free patients with T1D from long-term insulin dependence (i.e., no insulin injections or insulin pumps needed).
Should you be interested in learning more, please contact the study director to discuss next steps:
Email: [email protected]